Aquatic Capital Management LLC Boosts Holdings in InMode Ltd. (NASDAQ:INMD)

Aquatic Capital Management LLC raised its holdings in shares of InMode Ltd. (NASDAQ:INMD - Free Report) by 7,388.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 27,556 shares of the healthcare company's stock after acquiring an additional 27,188 shares during the quarter. Aquatic Capital Management LLC's holdings in InMode were worth $460,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. SBI Securities Co. Ltd. acquired a new position in shares of InMode during the 4th quarter worth approximately $87,000. Farther Finance Advisors LLC increased its position in InMode by 26.2% during the fourth quarter. Farther Finance Advisors LLC now owns 5,555 shares of the healthcare company's stock worth $93,000 after buying an additional 1,154 shares in the last quarter. Covestor Ltd raised its holdings in shares of InMode by 13.9% in the fourth quarter. Covestor Ltd now owns 5,936 shares of the healthcare company's stock worth $99,000 after acquiring an additional 723 shares during the last quarter. Pilgrim Partners Asia Pte Ltd purchased a new stake in shares of InMode in the fourth quarter valued at $114,000. Finally, Sterling Capital Management LLC boosted its stake in shares of InMode by 23.5% during the fourth quarter. Sterling Capital Management LLC now owns 9,162 shares of the healthcare company's stock valued at $153,000 after acquiring an additional 1,742 shares during the last quarter. Institutional investors and hedge funds own 68.04% of the company's stock.

InMode Stock Performance

INMD traded up $0.05 on Tuesday, reaching $14.30. 1,139,694 shares of the company's stock were exchanged, compared to its average volume of 1,190,260. The company has a market cap of $994.69 million, a price-to-earnings ratio of 6.09 and a beta of 2.02. InMode Ltd. has a twelve month low of $13.68 and a twelve month high of $19.85. The company's 50 day moving average is $16.79 and its 200-day moving average is $17.54.

InMode (NASDAQ:INMD - Get Free Report) last issued its earnings results on Monday, April 28th. The healthcare company reported $0.31 EPS for the quarter, missing analysts' consensus estimates of $0.45 by ($0.14). InMode had a net margin of 45.91% and a return on equity of 18.25%. The business had revenue of $77.87 million during the quarter, compared to analysts' expectations of $82.21 million. During the same period in the prior year, the business posted $0.32 EPS. The business's revenue was down 3.0% on a year-over-year basis. Sell-side analysts forecast that InMode Ltd. will post 1.75 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on INMD. Robert W. Baird downgraded InMode from an "outperform" rating to a "neutral" rating and cut their price target for the company from $22.00 to $16.00 in a report on Monday, April 28th. Barclays dropped their target price on InMode from $29.00 to $24.00 and set an "overweight" rating for the company in a research note on Wednesday, April 30th. BTIG Research lowered InMode from a "buy" rating to a "neutral" rating in a research note on Tuesday, April 29th. Needham & Company LLC reiterated a "hold" rating on shares of InMode in a report on Monday, April 28th. Finally, Baird R W cut shares of InMode from a "strong-buy" rating to a "hold" rating in a research report on Monday, April 28th. Seven research analysts have rated the stock with a hold rating and one has issued a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $18.54.

About InMode

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.